DK2191001T3 - Raav-vektorsammensætninger med tyrosinmodificerede capsidproteiner og fremgangsmåder til anvendelse deraf - Google Patents

Raav-vektorsammensætninger med tyrosinmodificerede capsidproteiner og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK2191001T3
DK2191001T3 DK08733161.7T DK08733161T DK2191001T3 DK 2191001 T3 DK2191001 T3 DK 2191001T3 DK 08733161 T DK08733161 T DK 08733161T DK 2191001 T3 DK2191001 T3 DK 2191001T3
Authority
DK
Denmark
Prior art keywords
promoter
disease
vectors
protein
cells
Prior art date
Application number
DK08733161.7T
Other languages
English (en)
Inventor
Li Zhong
Sergei Zolotukhin
Lakshmanan Govindasamy
Mavis Agbandje-Mckenna
Arun Srivastava
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Application granted granted Critical
Publication of DK2191001T3 publication Critical patent/DK2191001T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (7)

1. Rekombinant serotype 2-adenoassocieret virus (rAAV2)-vektor, der omfatter mindst én muteret overfladeeksponeret tyrosinrest på dens capsidprotein, hvilken mindst ene muterede tyrosinrest er udvalgt fra gruppen, der består af Tyr252, Tyr272, Tyr444, Tyr500, Tyr700, Tyr704, Tyr730, Tyr275, Tyr281, Tyr508, Tyr576, Tyr612, Tyr673 eller Tyr720. 2. rAAV-vektor ifølge krav 1, hvor den mindst ene mutered tyrosinrest er en eller flere af Tyr252, Tyr272, Tyr444, Tyr500, Tyr700, Tyr704 eller Tyr730. 3. rAAV-vektor ifølge krav 1 eller krav 2, der yderligere omfatter mindst et første nukleinsyresegment, der koder for mindst ét terapeutisk middel. 4. rAAV-vektor ifølge et hvilket som helst af ovennævnte krav, hvor den mindst ene muterede overfladeeksponerede tyrosinrest er substitueret med phenylalanin. 5. rAAV-vektor ifølge et hvilket som helst af ovennævnte krav, der yderligere omfatter en enhancersekvens, hvor enhanceren fortrinsvis er udvalgt fra gruppen, der består af en CMV-enhancer, en syntetisk enhancer, en leverspecifik enhancer, en vaskulær specifik enhancer, en hjernespecifik enhancer, en nervecellespecifik enhancer, en lungespecifik enhancer, en muskelspecifik enhancer, en nyrespecifik enhancer, en pankreasspecifik enhancer og en øcellespecifik enhancer. 6. rAAV-vektor ifølge et hvilket som helst af kravene 3 til 5, hvor ekspressionen af det terapeutiske middel kontrolleres af en promotor, hvor promotoren er en heterolog, vævsspecifik, konstitutiv eller inducerbar promotor og fortrinsvis én, der er udvalgt fra gruppen, der består af en CMV-promotor, en a-actinpromotor, en insulinpromotor, en enolasepromotor, en BDNF-promotor, en NGF-promotor, en EGF-promotor, en vækstfaktorpromotor, en axonspecifik promotor, en dendritspecifik promotor, en hjernespecifik promotor, en hippocampusspecifik promotor, en nyrespecifik promotor, en elafinpromotor, en cytokinpromotor, en interferonpromotor, en vækstfaktorpromotor, en og-antitrypsinpromotor, en hjernespecifik promotor, en neuralcellespecifik promotor, en central nervesystemcellespecifik promotor, en perifer nervesystemcellespecifik promotor, en interleukinpromotor, en serpinpromotor, en hybrid CMV-promotor, en hybrid a-actinpromotor, en EFl-promotor, en Ula-promotor, en Ulb-promotor, en Tet-inducerbar promotor og en VP16-lexA-promotor. 7. rAAV-vektor ifølge et hvilket som helst af kravene 3 til 6, hvor det mindst ene første nukleinsyresegment er yderligere operabelt koblet til en posttranskriptionel regulatorsekvens eller et polyadenyleringssignal og fortrinsvis til et posttranskriptionelt regulatorelement fra hepatitisvirus fra skovmurmeldyr. 8. rAAV-vektor ifølge et hvilket som helst af kravene 3 til 7, hvor det terapeutiske middel er udvalgt fra gruppen, der består af et polypeptid, et peptid, et antistof, et antigenbindende fragment, et ribozym, en peptidnukleinsyre, et siRNA, et RNAi, et antisense-oligonukleotid og et antisense-polynukleotid; fortrinsvis hvor det terapeutiske middel er et protein eller polypeptid, der er udvalgt fra gruppen, der består af en adrenerg agonist, en anti-apoptosefaktor, en apoptoseinhibitor, en cytokinreceptor, et cytokin, et cytotoksin, et erytropoietisk middel, en glutaminsyredecarboxylase, et glycoprotein, en vækstfaktor, en vækstfaktorreceptor, et hormon, en hormonreceptor, en interferon, et interleukin, en interleukinreceptor, en kinase, en kinaseinhibitor, en nervevækstfaktor, et netrin, et neuroaktivt peptid, en receptor for neuroaktivt peptid, en neurogen faktor, en receptor for neurogen faktor, et neuropilin, en neurotrofisk faktor, et neurotrophin, en neurotrophinreceptor, en N-methyl-D-aspartatantagonist, et plexin, en protease, en proteaseinhibitor, en proteindecarboxylase, en proteinkinase, en proteinkinaseinhibitor, et proteolytisk protein, en inhibitor af proteolytisk protein, et semaphorin, en semaphorinreceptor, et serotonintransportprotein, en serotoninoptagelsesinhibitor, en serotoninreceptor, et serpin, en serpinreceptor og en tumorsuppressor; og mere fortrinsvis hvor det terapeutiske middel er et polypeptid, der er udvalgt fra gruppen, der består af BDNF, CNTF, CSF, EGF, FGF, G-SCF, GMCSF, gonadotropin, I FN, IFG-1, M-CSF, NGF, PDGF, PEDF, TGF, TGF-B2, TNF, VEGF, prolactin, somatotropin, XIAP1, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL10(I87A), viral IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 og IL-18 . 9. rAAV-vektor ifølge et hvilket som helst af kravene 3 til 8, hvor det første nukleinsyresegment omfatter en sekvensregion, der koder for et peptid, et polypeptid, et antistof eller et antigenbindende fragment af human, murin, aviær, porcin, bovin, ovin, felin, canin, equin, epin, caprin, lupin (ulv) eller ikke-human primat oprindelse.
10. Isoleret mammaliaværtscelle, der omfatter rAAV-vektoren ifølge et hvilket som helst af ovennævnte krav, fortrinsvis en isoleret mammaliaværtscelle, der er udvalgt fra gruppen, der består af en human, ikke-human primat, murin, felin, canin, porcin, ovin, bovin, equin, epin, caprin og lupin værtscelle; og mere fortrinsvis en isoleret human endotel-, epitel-, vaskulær-, lever-, lunge-, hjerte-, pankreas-, intestinal-, nyre-, muskel-, knogle-, nerve-, blod- eller hjernecelle. 11. rAAV-vektor ifølge et hvilket som helst af kravene 1 til 9 til anvendelse til terapi. 12. rAAV-vektor ifølge et hvilket som helst af kravene 1 til 9 til anvendelse til diagnosticering, forebyggelse, behandling eller lindring af et eller flere symptomer på en sygdom, en skade, en forstyrrelse, et traume eller en dysfunktion hos et pattedyr og yderligere fortrinsvis til anvendelse til behandling, forebyggelse eller lindring af et eller flere symptomer på cancer, diabetes, autoimmunsygdom, nyresygdom, kardiovaskulær sygdom, pankreassygdom, intestinal sygdom, leversygdom, neurologisk sygdom, neuromuskulær forstyrrelse, neuromotorisk funktionsforstyrrelse, nedsat neuroskeletfunktion, nedsat neurologisk funktion, neurosensorisk dysfunktion, apopleksi, iskæmi, spiseforstyrrelse, og-antitrypsin (AAT)-mangel, Battens sygdom, Alzheimers sygdom, Huntingtons sygdom, Parkinsons sygdom, skeletsygdom, traume eller lungesygdom hos et pattedyr.
13. Anvendelse af rAAV-vektoren ifølge et hvilket som helst af kravene 1 til 9 til fremstilling af et medikament til anvendelse til diagnosticering, forebyggelse, behandling eller lindring af et eller flere symptomer på en sygdom, en skade, en forstyrrelse, et traume eller en dysfunktion hos et pattedyr og yderligere fortrinsvis til anvendelse til behandling, forebyggelse eller lindring af et eller flere symptomer på cancer, diabetes, autoimmunsygdom, nyresygdom, kardiovaskulær sygdom, pankreassygdom, intestinal sygdom, leversygdom, neurologisk sygdom, neuromuskulær forstyrrelse, neuromotorisk funktionsforstyrrelse, nedsat neuroskeletfunktion, nedsat neurologisk funktion, neurosensorisk dysfunktion, apopleksi, iskæmi, spiseforstyrrelse, og-antitrypsin (AAT)-mangel, Battens sygdom, Alzheimers sygdom, Huntingtons sygdom, Parkinsons sygdom, skeletsygdom, traume eller lungesygdom hos et pattedyr.
14. Fremgangsmåde til forøgelse af transduktionseffektiviteten af en rekombinant adenoassocieret virus (rAAV)-vektor, hvilken fremgangsmåde omfatter trinet mutering af mindst én overfladeeksponeret tyrosinrest i capsidproteinerne, hvor den mindst ene overfladeeksponerede tyrosinrest svarer til Tyr252, Tyr272, Tyr444, Tyr500, Tyr700, Tyr704, Tyr730, Tyr275, Tyr281, Tyr508, Tyr576, Tyr612, Tyr673 eller Tyr720 i vildtype-AAV2-capsidproteinet, således at transduktionseffektiviteten i en mammaliacelle af vektoren, der omfatter det muterede capsidprotein, er højere end transduktionseffektiviteten for en tilsvarende AAV, der opretholder de overfladeeksponerede tyrosinrester i capsidproteinet, hvor mammaliaværtscellen er den humane cervikalcellelinje HeLa.
15. Fremgangsmåde ifølge krav 14, hvor den mindst ene muterede tyrosinrest er en eller flere af Tyr252, Tyr272, Tyr444, Tyr500, Tyr700, Tyr704 eller Tyr730.
16. Fremgangsmåde ifølge krav 14 eller 15, hvor den mindst ene muterede overfladeeksponerede tyrosinrest er substitueret med phenylalanin.
17. Fremgangsmåde ifølge krav 14, 15 eller 16, hvor den rekombinante adenoassocierede virus (rAAV)-vektor er udvalgt fra gruppen, der består af en AAV-serotype 1, en AAV-serotype 2, en AAV-serotype 3, en AAV-serotype 4, en AAV-serotype 5 og en AAV-serotype 6.
DK08733161.7T 2007-04-09 2008-04-08 Raav-vektorsammensætninger med tyrosinmodificerede capsidproteiner og fremgangsmåder til anvendelse deraf DK2191001T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91079807P 2007-04-09 2007-04-09
PCT/US2008/059647 WO2008124724A1 (en) 2007-04-09 2008-04-08 Raav vector compositions having tyrosine-modified capsid proteins and methods for use

Publications (1)

Publication Number Publication Date
DK2191001T3 true DK2191001T3 (da) 2016-09-19

Family

ID=39684174

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08733161.7T DK2191001T3 (da) 2007-04-09 2008-04-08 Raav-vektorsammensætninger med tyrosinmodificerede capsidproteiner og fremgangsmåder til anvendelse deraf
DK13154078.3T DK2623605T3 (da) 2007-04-09 2008-04-08 Raav-vektorsammensætninger med tyrosinmodificerede capsidproteiner og fremgangsmåder til anvendelse deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13154078.3T DK2623605T3 (da) 2007-04-09 2008-04-08 Raav-vektorsammensætninger med tyrosinmodificerede capsidproteiner og fremgangsmåder til anvendelse deraf

Country Status (13)

Country Link
US (11) US8445267B2 (da)
EP (3) EP3492596A1 (da)
CA (1) CA2720097C (da)
CY (1) CY1118228T1 (da)
DK (2) DK2191001T3 (da)
ES (3) ES2714007T3 (da)
HR (1) HRP20161150T1 (da)
HU (1) HUE030719T2 (da)
LT (2) LT2191001T (da)
PL (1) PL2191001T3 (da)
PT (1) PT2191001T (da)
SI (1) SI2191001T1 (da)
WO (1) WO2008124724A1 (da)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9725485B2 (en) 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
EP3492596A1 (en) 2007-04-09 2019-06-05 University of Florida Research Foundation, Inc. Raav vector compositions having tyrosine-modified capsid proteins and methods for use
US9611302B2 (en) 2007-04-09 2017-04-04 University Of Florida Research Foundation, Inc. High-transduction-efficiency RAAV vectors, compositions, and methods of use
CA2762118A1 (en) * 2008-05-20 2010-01-28 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8840881B2 (en) * 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
GB2492719A (en) 2010-04-05 2013-01-09 Eos Neuroscience Inc Methods and compositions for decreasing chronic pain
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
DK2826860T3 (da) 2010-04-23 2018-12-03 Univ Massachusetts CNS-targeting AAV-vektorer og fremgangsmåder til anvendelse deraf
US9546369B2 (en) 2010-04-23 2017-01-17 University Of Massachusetts Multicistronic expression constructs
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
WO2012051599A2 (en) 2010-10-15 2012-04-19 Eos Neuroscience, Inc. Modulation neural pathways
CN103189507A (zh) * 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
ES2661680T3 (es) 2011-04-21 2018-04-03 University Of Massachusetts Composiciones basadas en VAAr y métodos para tratar deficiencias de alfa-1 anti-tripsina
EP2660325A3 (en) * 2012-05-02 2014-02-12 Christian Medical College AAV vectors and corresponding nucleotide sequences and methods
EP3470523A1 (en) * 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
US10294281B2 (en) 2012-05-15 2019-05-21 University Of Florida Research Foundation, Incorporated High-transduction-efficiency rAAV vectors, compositions, and methods of use
EP3738974A1 (en) 2012-09-28 2020-11-18 The University of North Carolina at Chapel Hill Aav vectors targeted to oligodendrocytes
CN105408486B (zh) * 2013-05-21 2020-07-14 佛罗里达大学研究基金会有限公司 衣壳修饰的raav3载体组合物以及在人肝癌基因治疗中的用途
JP6985795B2 (ja) 2013-09-26 2021-12-22 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 標的遺伝子治療のための合成コンビナトリアルａａｖカプシドライブラリー
US10072251B2 (en) 2014-02-19 2018-09-11 University Of Massachusetts Recombinant AAVS having useful transcytosis properties
WO2015126972A1 (en) * 2014-02-21 2015-08-27 University Of Florida Research Foundation, Inc. Methods and compositions for gene delivery to on bipolar cells
US10308957B2 (en) 2014-03-04 2019-06-04 University Of Florida Research Foundation, Inc. rAAV vectors and methods for transduction of photoreceptors and RPE cells
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
US10711270B2 (en) 2014-10-03 2020-07-14 University Of Massachusetts High efficiency library-identified AAV vectors
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
ES2878451T3 (es) 2014-11-14 2021-11-18 Voyager Therapeutics Inc Polinucleótidos moduladores
AU2015346162B2 (en) 2014-11-14 2022-02-10 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US10900053B2 (en) 2014-11-21 2021-01-26 University Of Florida Research Foundation, Incorporated Genome-modified recombinant adeno-associated virus vectors
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
US20180030096A1 (en) 2015-02-03 2018-02-01 University Of Florida Research Foundation, Inc. Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
WO2016131009A1 (en) 2015-02-13 2016-08-18 University Of Massachusetts Compositions and methods for transient delivery of nucleases
US10648000B2 (en) 2015-02-16 2020-05-12 University Of Florida Research Foundation, Incorporated rAAV vector compositions, methods for targeting vascular endothelial cells and use in treatment of type I diabetes
US20180044698A1 (en) * 2015-02-19 2018-02-15 University Of Florida Research Foundation, Incorporated Site-specific integrating recombinant aav vectors for gene therapy and improved production methods
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
CA2996420A1 (en) 2015-09-28 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
US11426469B2 (en) 2015-10-22 2022-08-30 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
WO2017070525A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Methods and compositions for treating metabolic imbalance in neurodegenerative disease
GB201519086D0 (en) 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
US10983110B2 (en) 2015-12-02 2021-04-20 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
JP6996728B2 (ja) * 2016-01-07 2022-01-17 学校法人自治医科大学 グルコーストランスポーター１発現用アデノ随伴ウイルスベクター
CN118048321A (zh) 2016-01-13 2024-05-17 建新公司 用于治疗哺乳动物内骨关节炎和相关关节病症的表达骨保护性基因、包括has2和润滑素的重组aav载体
EP3411059A4 (en) 2016-02-02 2019-10-16 University Of Massachusetts METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
DK3436051T3 (da) 2016-03-31 2021-11-01 Spark Therapeutics Inc Søjlebaseret fuldt skalérbar raav-fremstillingsfremgangsmåde.
US11413356B2 (en) 2016-04-15 2022-08-16 University Of Massachusetts Methods and compositions for treating metabolic imbalance
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
ES2941502T3 (es) 2016-05-13 2023-05-23 4D Molecular Therapeutics Inc Variantes de cápsides de virus adenoasociado y procedimientos de utilización de las mismas
WO2017201121A1 (en) * 2016-05-17 2017-11-23 University Of Florida Research Foundation, Inc. Recombinant aav for gene therapy in lungs
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
MX2018014152A (es) 2016-05-18 2019-03-28 Voyager Therapeutics Inc Composiciones y métodos para tratar la enfermedad de huntington.
WO2017218852A1 (en) 2016-06-15 2017-12-21 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
WO2018033542A1 (en) 2016-08-15 2018-02-22 Danmarks Tekniske Universitet Method for reducing ammonium and lactate production in cho cells
CA3035522A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US10650621B1 (en) 2016-09-13 2020-05-12 Iocurrents, Inc. Interfacing with a vehicular controller area network
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
KR20190075964A (ko) 2016-10-13 2019-07-01 유니버시티 오브 매사추세츠 Aav 캡시드 설계
EP3569708A4 (en) 2017-01-13 2020-09-09 Jichi Medical University AAV VECTOR TO DISCONNECT THE COOLAGE RELATED FACTOR ON THE LIVER GENOME
WO2018139634A1 (ja) 2017-01-30 2018-08-02 学校法人日本医科大学 アデノ随伴ウイルス（ａａｖ）キャプシドタンパク質の変異体
AU2018224044B2 (en) 2017-02-21 2024-01-25 The Uab Research Foundation Modified AAV capsid proteins and uses thereof
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
BR112020005436B1 (pt) 2017-09-20 2022-08-02 4D Molecular Therapeutics Inc Proteína do capsídeo de variante do vírus adenoassociado, virion do aav recombinante (raav) infeccioso, composições, composições farmacêuticas e usos de virion de raav ou de composições farmacêuticas
EP4124658A3 (en) 2017-10-16 2023-04-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
AU2018372235B9 (en) 2017-11-27 2022-03-10 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
US10806802B2 (en) 2018-01-18 2020-10-20 University Of Guelph Adeno-associated virus particle with mutated capsid and methods of use thereof
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
EP3755795A4 (en) 2018-02-19 2022-07-20 Homology Medicines, Inc. ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RECOVERING F8 GENE FUNCTION AND METHODS OF USE THEREOF
SG11202009451VA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
MX2020010464A (es) 2018-04-03 2021-01-29 Vectores de virus que evitan anticuerpos.
CA3094465A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
WO2019210249A1 (en) * 2018-04-26 2019-10-31 Oregon Health & Science University Methods of aav vector production by modulating deubiquitinating enzyme activity
WO2019210267A2 (en) * 2018-04-27 2019-10-31 Spark Therapeutics, Inc. Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
AU2019270900A1 (en) * 2018-05-15 2020-10-15 President And Fellows Of Harvard College Viral vectors exhibiting improved gene delivery properties
JPWO2020026968A1 (ja) 2018-07-30 2021-08-12 株式会社遺伝子治療研究所 Ａａｖベクターによる遺伝子発現を増強する方法
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201821089D0 (en) 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
GB201821082D0 (en) 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
WO2020174368A1 (en) 2019-02-25 2020-09-03 Novartis Ag Compositions and methods to treat bietti crystalline dystrophy
US20220154211A1 (en) 2019-02-25 2022-05-19 Novartis Ag Compositions and methods to treat bietti crystalline dystrophy
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
AU2020310201A1 (en) 2019-07-10 2022-01-27 Locanabio, Inc. RNA-targeting knockdown and replacement compositions and methods for use
WO2021009805A1 (ja) 2019-07-12 2021-01-21 株式会社遺伝子治療研究所 ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
US20220347298A1 (en) 2019-10-04 2022-11-03 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
CA3157700A1 (en) 2019-10-17 2021-04-22 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
IL294868A (en) 2020-01-29 2022-09-01 Genzyme Corp Adeno-associated viral capsid proteins modified for eye gene therapy and methods of using them
CA3171166A1 (en) 2020-02-13 2021-08-19 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
WO2021163357A2 (en) 2020-02-13 2021-08-19 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
BR112022015921A2 (pt) 2020-02-14 2022-10-04 Ultragenyx Pharmaceutical Inc Terapia gênica para tratar o transtorno de deficiência de cdkl5
WO2021188892A1 (en) 2020-03-19 2021-09-23 Ultragenyx Pharmaceutical Inc. Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
EP4127189A1 (en) 2020-03-31 2023-02-08 Ultragenyx Pharmaceutical Inc. Gene therapy for treating propionic acidemia
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
EP4200408A1 (en) 2020-08-19 2023-06-28 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of rett syndrome
CA3173768A1 (en) 2020-10-13 2022-04-21 Brian Furmanski Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
JP2023545229A (ja) 2020-10-16 2023-10-27 ジャイロスコープ・セラピューティクス・リミテッド 抗ｖｅｇｆ実体および負の補体調節因子をコードする核酸、ならびに加齢黄斑変性の処置のためのその使用
WO2022119974A1 (en) 2020-12-01 2022-06-09 Locanabio, Inc. Rna-targeting compositions and methods for treating cag repeat diseases
US20240108751A1 (en) 2020-12-01 2024-04-04 Locanabio, Inc. Rna-targeting compositions and methods for treating myotonic dystrophy type 1
WO2022221278A1 (en) 2021-04-12 2022-10-20 Locanabio, Inc. Compositions and methods comprising hybrid promoters
CN113121655B (zh) * 2021-04-19 2021-11-19 上海信致医药科技有限公司 眼部和肌肉特异靶向型腺相关病毒载体及其应用
JPWO2022224372A1 (da) 2021-04-21 2022-10-27
EP4367251A1 (en) 2021-07-08 2024-05-15 Tenaya Therapeutics, Inc. Optimized expression cassettes for gene therapy
JP2024531138A (ja) 2021-08-11 2024-08-29 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 筋ジストロフィーを処置するための組成物および方法
EP4458842A1 (en) * 2021-11-30 2024-11-06 Glugenetherapeutics Inc. Mutant of adeno-associated virus capsid protein
EP4446419A1 (en) 2021-12-06 2024-10-16 Jichi Medical University Recombinant adeno-associated virus vector for treatment of iron-accumulating neurodegenerative diseases
WO2023154807A2 (en) 2022-02-09 2023-08-17 Locanabio, Inc. Compositions and methods for modulating pre-mrna splicing
US20230279397A1 (en) 2022-03-04 2023-09-07 Locanabio, Inc. Compositions and methods comprising engineered short nuclear rna (snrna)
AU2023232781A1 (en) 2022-03-07 2024-09-26 Ultragenyx Pharmaceutical Inc. Modified batch aav production systems and methods
WO2023205637A1 (en) 2022-04-18 2023-10-26 Locanabio, Inc. Rna-targeting compositions and methods for treating c9/orf72 diseases
WO2023250447A2 (en) * 2022-06-22 2023-12-28 Synvivia, Inc. Methods of selection and use of engineered cyclic peptides for enhancing viral production
WO2024054864A1 (en) 2022-09-06 2024-03-14 Tenaya Therapeutics, Inc. Cardioprotective heart disease therapies
WO2024086650A1 (en) 2022-10-18 2024-04-25 Locanabio, Inc. Compositions and methods comprising programmable snrnas for rna editing
WO2024119102A1 (en) 2022-12-01 2024-06-06 Locanabio, Inc. Adeno-associated viral vectors for proper packaging of repetitive elements
WO2024161142A1 (en) 2023-02-02 2024-08-08 Quethera Limited Recombinant adeno-associated virus vector
WO2024215655A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Cardioprotective bag3 therapies
WO2024215653A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Guide rnas, vectors, and virions for targeting mutations in the pln gene

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105A (en) 1836-12-15 knight
US106A (en) 1915-08-24 Specipication
US103A (en) 1836-12-10 Process
US102A (en) 1861-08-13 Whole
US104A (en) 1836-12-10 Revolving hokse-rake
EP0003048B2 (de) 1978-01-05 1983-08-24 Bayer Ag Formmassen auf der Grundlage ungesättigter Polyester, Verfahren zu ihrer Herstellung und ihre Verwendung
US4216209A (en) 1979-03-19 1980-08-05 American Home Products Corporation Tripeptide angiotensin converting enzyme inhibitors
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5037746A (en) 1986-12-03 1991-08-06 University Patents, Inc. RNA ribozyme polymerases, and methods
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
WO1989006700A1 (en) 1988-01-21 1989-07-27 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4932207A (en) 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
AU6505690A (en) 1989-09-26 1991-04-28 Richard R Behringer Erythroid-specific gene expression system
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
JPH03251543A (ja) 1990-02-26 1991-11-11 Unitika Ltd アンジオテンシン変換酵素阻害剤
EP0445606B1 (en) 1990-02-27 1997-01-22 The Agency of Industrial Science and Technology Novel oligopeptides, pharmaceutical composition and food containing the same, and use of oligopeptides
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
ATE120453T1 (de) 1990-06-22 1995-04-15 Fisons Plc Inhibitoren fur angiotensin umwandelnde enzyme.
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
JPH07506720A (ja) 1992-01-07 1995-07-27 アテナ　ニューロサイエンシーズ，　インコーポレイテッド アルツハイマー病のトランスジェニック動物モデル
US5552397A (en) 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5646020A (en) 1992-05-14 1997-07-08 Ribozyme Pharmaceuticals, Inc. Hammerhead ribozymes for preferred targets
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5297721A (en) 1992-11-19 1994-03-29 Fry's Metals, Inc. No-clean soldering flux and method using the same
US5639655A (en) 1993-01-19 1997-06-17 Ribozyme Pharmaceuticals, Inc. PML-RARA targeted ribozymes
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5639940A (en) 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US5789655A (en) 1994-05-13 1998-08-04 The Regents Of The University Of California Transgenic animals expressing artificial epitope-tagged proteins
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5646031A (en) 1995-05-16 1997-07-08 Northern Illinois University SArMV and sCYMVI hairpin ribozymes
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5779708A (en) 1996-08-15 1998-07-14 Cyberdent, Inc. Intraosseous drug delivery device and method
US5863736A (en) 1997-05-23 1999-01-26 Becton, Dickinson And Company Method, apparatus and computer program products for determining quantities of nucleic acid sequences in samples
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US7052692B1 (en) 1997-09-02 2006-05-30 Advanced Research & Technology Institute Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
CA2453405A1 (en) 2001-07-13 2003-01-23 University Of Iowa Research Foundation Pseudotyped adeno-associated viruses and uses thereof
NZ618298A (en) * 2001-11-13 2015-04-24 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
EP3339430A1 (en) * 2001-12-17 2018-06-27 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses thereof
EP2278020A3 (en) 2002-04-09 2011-05-11 Nationwide Children's Hospital, Inc. Antibody gene transfer and recombinant AAV therefor
US20060292117A1 (en) 2002-04-17 2006-12-28 Loiler Scott A Improved rAAv vectors
DE60323078D1 (de) 2002-05-01 2008-10-02 Univ Florida Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
JP5054975B2 (ja) * 2003-09-30 2012-10-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア アデノ随伴ウイルス（ａａｖ）の同源系統群、配列、それらを含有するベクターおよびそれらの用途
CN117363655A (zh) * 2005-04-07 2024-01-09 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
WO2006119150A2 (en) 2005-04-29 2006-11-09 Beth Israel Deaconess Medical Center Compositions and methods for targeting of viral vectors
US9611302B2 (en) 2007-04-09 2017-04-04 University Of Florida Research Foundation, Inc. High-transduction-efficiency RAAV vectors, compositions, and methods of use
EP3492596A1 (en) 2007-04-09 2019-06-05 University of Florida Research Foundation, Inc. Raav vector compositions having tyrosine-modified capsid proteins and methods for use
US9725485B2 (en) 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
CA2762118A1 (en) 2008-05-20 2010-01-28 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives
DK2826860T3 (da) 2010-04-23 2018-12-03 Univ Massachusetts CNS-targeting AAV-vektorer og fremgangsmåder til anvendelse deraf
CN103189507A (zh) 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
US9409953B2 (en) 2011-02-10 2016-08-09 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
US9909142B2 (en) 2012-04-18 2018-03-06 The Children's Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using AAV capsid variants
EP2660325A3 (en) 2012-05-02 2014-02-12 Christian Medical College AAV vectors and corresponding nucleotide sequences and methods
US10294281B2 (en) 2012-05-15 2019-05-21 University Of Florida Research Foundation, Incorporated High-transduction-efficiency rAAV vectors, compositions, and methods of use
US20230136849A1 (en) * 2012-05-15 2023-05-04 University Of Florida Research Foundation, Incorporated Capsid-modified raav vector compositions and methods therefor
CN103060331B (zh) 2012-12-05 2014-10-08 南京医科大学第一附属医院 介导膜稳定cd40l基因的衣壳蛋白突变的双链重组腺相关病毒制备方法与应用
US10308957B2 (en) 2014-03-04 2019-06-04 University Of Florida Research Foundation, Inc. rAAV vectors and methods for transduction of photoreceptors and RPE cells
AU2015229464B2 (en) * 2014-03-11 2021-07-22 Wayne State University A modified mGluR6 promoter and methods of use
US20180030096A1 (en) 2015-02-03 2018-02-01 University Of Florida Research Foundation, Inc. Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
WO2016134338A1 (en) 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Recombinant aav vectors for gene therapy of human hematopoietic disorders
US20190000943A1 (en) 2015-08-13 2019-01-03 Aavet Therapeutics, Llc Aav6 vectors for immunotherapy

Also Published As

Publication number Publication date
US20210040156A1 (en) 2021-02-11
US20160106865A1 (en) 2016-04-21
EP2623605A1 (en) 2013-08-07
US20180244727A1 (en) 2018-08-30
ES2599632T3 (es) 2017-02-02
LT2999791T (lt) 2019-05-27
US20130203841A1 (en) 2013-08-08
US20140050701A1 (en) 2014-02-20
US9920097B2 (en) 2018-03-20
EP3492596A1 (en) 2019-06-05
US10934327B2 (en) 2021-03-02
EP2623605B1 (en) 2018-11-28
US20180223312A1 (en) 2018-08-09
US9775918B2 (en) 2017-10-03
US20180036428A1 (en) 2018-02-08
US8445267B2 (en) 2013-05-21
CA2720097A1 (en) 2008-10-16
ES2714292T3 (es) 2019-05-28
US9157098B2 (en) 2015-10-13
US20160333372A1 (en) 2016-11-17
PL2191001T4 (pl) 2017-01-31
US10723768B2 (en) 2020-07-28
SI2191001T1 (sl) 2017-01-31
DK2623605T3 (da) 2019-03-25
LT2191001T (lt) 2016-10-10
EP2191001A1 (en) 2010-06-02
PL2191001T3 (pl) 2017-01-31
HRP20161150T1 (hr) 2016-11-18
CY1118228T1 (el) 2017-06-28
ES2714007T3 (es) 2019-05-24
EP2191001B1 (en) 2016-06-08
HUE030719T2 (en) 2017-05-29
WO2008124724A1 (en) 2008-10-16
US20100104561A1 (en) 2010-04-29
PT2191001T (pt) 2016-09-23
US20210253644A1 (en) 2021-08-19
US20130216501A1 (en) 2013-08-22
US8802440B2 (en) 2014-08-12
CA2720097C (en) 2016-07-19

Similar Documents

Publication Publication Date Title
US20210040156A1 (en) Capsid-modified raav vectors and methods of use
US10308957B2 (en) rAAV vectors and methods for transduction of photoreceptors and RPE cells
US10413598B2 (en) Factor IX gene therapy
JP7371954B2 (ja) ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
WO2023012313A1 (en) Hybrid promoters for gene expression in muscles and in the cns
JP2021097617A (ja) オルニチントランスカルバミラーゼ欠損症の治療用アデノ随伴ウイルスビリオン
US11779655B2 (en) AAV-ABCD1 constructs and use for treatment or prevention of adrenoleukodystrophy (ALD) and/or adrenomyeloneuropathy (AMN)
RU2825667C2 (ru) Выделенный модифицированный белок VPI капсида аденоассоциированного вируса 9 серотипа (AAV9), капсид и вектор на его основе
RU2820088C1 (ru) Выделенный модифицированный белок VPI капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
WO2022224372A1 (ja) オルニチントランスカルバミラーゼ欠損症の治療用アデノ随伴ウイルスビリオン
WO2023022633A1 (ru) Выделенный модифицированный белок vp1 капсида aav5